We are live on ! Find out more
ICPT

Intercept Pharmaceuticals, Inc.
ICPT

Delisted

ICPT was delisted on the 7th of November, 2023.

Back to rankings

181 hedge funds and large institutions have $3.05B invested in Intercept Pharmaceuticals, Inc. in 2014 Q3 according to their latest regulatory filings, with 37 funds opening new positions, 81 increasing their positions, 47 reducing their positions, and 21 closing their positions.

New
Increased
Maintained
Reduced
Closed

100% more funds holding in top 10

Funds holding in top 10: 1 → 2 (+1)

76% more first-time investments, than exits

New positions opened: 37 | Existing positions closed: 21

72% more repeat investments, than reductions

Existing positions increased: 81 | Existing positions reduced: 47

8% more funds holding

Funds holding: 167 → 181 (+14)

2% less capital invested

Capital invested by funds: $3.12B → $3.05B (-$62.2M)

39% less call options, than puts

Call options by funds: $109M | Put options by funds: $179M

Holders
181
Holders Change
+14
Holders Change %
+8.38%
% of All Funds
5.25%
Holding in Top 10
2
Holding in Top 10 Change
+1
Holding in Top 10 Change %
+100%
% of All Funds
0.06%
New
37
Increased
81
Reduced
47
Closed
21
Calls
$109M
Puts
$179M
Net Calls
-$69.4M
Net Calls Change
+$62.5M

Top Buyers

Rank Fund Capital Flow
1
CG
Carmignac Gestion
France
+$84.1M
2
Millennium Management
Millennium Management
New York
+$74.9M
3
CCI
Columbus Circle Investors
+$39.2M
4
Susquehanna International Group
Susquehanna International Group
Pennsylvania
+$38.3M
5
Franklin Resources
Franklin Resources
California
+$35.4M

Top Sellers

Rank Fund Capital Flow
1
Jennison Associates
Jennison Associates
New York
-$298M
2
T. Rowe Price Associates
T. Rowe Price Associates
Maryland
-$91.6M
3
Viking Global Investors
Viking Global Investors
Connecticut
-$49.2M
4
O
OrbiMed
New York
-$43.7M
5
Norges Bank
Norges Bank
Norway
-$31.4M
Name Holding Trade Value Shares
Change 		Change in
Stake
RFC
26
Russell Frank Company
Washington
$18.9M +$8.45M +33,150 +71%
FAM
27
Fred Alger Management
New York
$18.9M -$4.69M -18,390 -19%
SAM
28
Sectoral Asset Management
Quebec, Canada
$18.4M +$994K +3,900 +5%
SCM
29
Suffolk Capital Management
New York
$14.8M +$5.2M +20,381 +48%
Geode Capital Management
30
Geode Capital Management
Massachusetts
$14.8M +$212K +832 +1%
CA
31
Commerzbank Aktiengesellschaft
Germany
$14M +$6.92M +27,144 +85%
AGA
32
Altrinsic Global Advisors
Connecticut
$12M – – –
Nomura Holdings
33
Nomura Holdings
Japan
$12M +$2.16M +8,477 +20%
Northern Trust
34
Northern Trust
Illinois
$11.4M -$13.6M -53,249 -53%
TI
35
Turner Investments
Pennsylvania
$11.2M +$10.3M +40,235 +579%
TCIM
36
TIAA CREF Investment Management
New York
$10M +$2.21M +8,668 +26%
Adage Capital Partners
37
Adage Capital Partners
Massachusetts
$9.7M +$6.63M +26,000 +173%
CS
38
Credit Suisse
Switzerland
$9.14M +$4.31M +16,899 +78%
Point72 Asset Management
39
Point72 Asset Management
Connecticut
$8.83M +$2.75M +10,800 +41%
VanEck Associates
40
VanEck Associates
New York
$8.76M -$107K -419 -1%
Two Sigma Investments
41
Two Sigma Investments
New York
$8.36M +$5.85M +22,955 +186%
Artisan Partners
42
Artisan Partners
Wisconsin
$7.11M +$7.66M +30,050 New
GC
43
Guggenheim Capital
Illinois
$6.99M +$675K +2,647 +10%
Goldman Sachs
44
Goldman Sachs
New York
$6.97M -$5.19M -20,344 -41%
Allianz Asset Management
45
Allianz Asset Management
Germany
$6.83M +$4.19M +16,415 +132%
WMSA
46
Weiss Multi-Strategy Advisers
New York
$6.46M +$331K +1,300 +5%
CCM
47
Cadian Capital Management
New York
$5.92M +$6.37M +25,000 New
AQR Capital Management
48
AQR Capital Management
Connecticut
$5.82M +$4.27M +16,757 +214%
Charles Schwab
49
Charles Schwab
California
$5.46M +$1.57M +6,173 +37%
PP
50
PDT Partners
New York
$5.45M +$5.87M +23,011 New
1
2
3 4 5

ICPT Hedge Fund Activity: Q3 2014 in Review

181 of the 3,446 institutional investors tracked by Wall St. Rank reported a position in Intercept Pharmaceuticals, Inc. (ICPT) for Q3 2014, worth a combined $3.05B — down 2% from $3.12B a quarter earlier.

Buyers outnumbered sellers: 37 funds opened new ICPT positions and 21 closed out — a net gain of 16 holders — while 81 added to existing stakes and 47 trimmed.

The largest buyer was Carmignac Gestion, adding an estimated $84.1M. The largest seller was Jennison Associates, cutting an estimated $298M.

  • 181 institutional investors held Intercept Pharmaceuticals, Inc. (ICPT) as of Q3 2014, up from 167 in Q2 2014.
  • Funds reported $3.05B of Intercept Pharmaceuticals, Inc. stock for Q3 2014, down 2% quarter-over-quarter.
  • 37 funds opened new Intercept Pharmaceuticals, Inc. positions in Q3 2014 and 21 closed out, a net change of +16 holders.
  • The largest Intercept Pharmaceuticals, Inc. buyer in Q3 2014 was Carmignac Gestion, an estimated $84.1M added.
  • The largest Intercept Pharmaceuticals, Inc. seller in Q3 2014 was Jennison Associates, an estimated $298M sold.

Based on aggregated 13F filings for Q3 2014.